21 January 2025
21 January 2025
The healthcare industry has shared its concerns on a global scale after President Trump signed the executive order.
Whilst vaccines exist for animals, none are commercially available for human use for the mosquito-borne virus.
The deal highlights the growing trend of China-derived experimental therapies entering the US market.
The expanded approval is based on the outcomes from Part I of the RUBY Phase III trial.
The funds aim to expedite late-stage development and licensing of the company's pre-pandemic mRNA vaccines.
These initiatives represent a way to accelerate access to treatments that have historically faced longer regulatory pathways.
The authorisation is supported by outcomes from two Phase III trials.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
